Special Issue "Hsp90 Inhibitors"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (30 May 2012)

Special Issue Editor

Guest Editor
Dr. Kip West
Section of Pharmacology, Infinity Pharmaceuticals, 780 Memorial Drive, Cambridge, MA 02139, USA
E-Mail: kip.west@infi.com
Interests: HSP90; PI3K/AKT/mTOR signaling pathway; RAS/RAF/MEK signaling pathway; EGFR/ErbB family signaling pathway(s); Cancer; Non-small cell lung cancer; colorectal cancer; pancreatic cancer

Special Issue Information

Dear Colleagues,

Cancer is a disease that has been demonstrated to involve the dysregulation of a minority of different key proteins or signaling pathways within cells which manifests itself in the aberrant expression and/or function of these proteins/pathways. Heat shock protein 90 (Hsp90) has been shown to play an integral role in regulating the stability of a number of these key cancer-causing proteins through its role as a protein chaperone. Proteins chaperoned by Hsp90, known as client proteins, include cancer-causing forms of ALK, BCR-ABL, EGFR, FLT3, and HER2. This role in controlling the activity of multiple client proteins makes Hsp90 an attractive target for therapeutic intervention. Indeed, Infinity Pharmaceuticals, as well as others, have shown the potential clinical utility of inhibiting Hsp90 function in the management of different malignancies including non-small cell lung cancer, gastro-intestinal stromal tumors and breast cancer. The purpose of this special issue is to evaluate the current status of Hsp90 inhibitors in preclinical and clinical development, review historical findings and examine where this exciting area of research and therapeutic development will lead in the future.

Dr. Kip A. West
Guest Editor

Published Papers (8 papers)

Download All Papers
Sort by:
Display options:
Select articles Export citation of selected articles as:
Select/unselect all
Displaying article 1-8
p. 1008-1020
by , ,  and
Pharmaceuticals 2012, 5(9), 1008-1020; doi:10.3390/ph5091008
Received: 19 July 2012; in revised form: 30 August 2012 / Accepted: 10 September 2012 / Published: 12 September 2012
Show/Hide Abstract | Cited by 1 | PDF Full-text (190 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Hsp90 Inhibitors)
p. 944-962
by ,  and
Pharmaceuticals 2012, 5(9), 944-962; doi:10.3390/ph5090944
Received: 5 July 2012; in revised form: 28 August 2012 / Accepted: 31 August 2012 / Published: 10 September 2012
Show/Hide Abstract | Cited by 1 | PDF Full-text (903 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Hsp90 Inhibitors)
p. 890-898
by ,  and
Pharmaceuticals 2012, 5(9), 890-898; doi:10.3390/ph5090890
Received: 6 July 2012; in revised form: 20 August 2012 / Accepted: 24 August 2012 / Published: 30 August 2012
Show/Hide Abstract | Cited by 1 | PDF Full-text (235 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Hsp90 Inhibitors)
p. 779-801
by , ,  and
Pharmaceuticals 2012, 5(8), 779-801; doi:10.3390/ph5080779
Received: 4 June 2012; in revised form: 9 July 2012 / Accepted: 16 July 2012 / Published: 25 July 2012
Show/Hide Abstract | Cited by 2 | PDF Full-text (317 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Hsp90 Inhibitors)
p. 674-689
by , , ,  and
Pharmaceuticals 2012, 5(7), 674-689; doi:10.3390/ph5070674
Received: 20 April 2012; in revised form: 13 June 2012 / Accepted: 21 June 2012 / Published: 28 June 2012
Show/Hide Abstract | Cited by 2 | PDF Full-text (620 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Hsp90 Inhibitors)
p. 1488-1502
by , , , ,  and
Pharmaceuticals 2011, 4(11), 1488-1502; doi:10.3390/ph4111488
Received: 1 September 2011; in revised form: 1 November 2011 / Accepted: 7 November 2011 / Published: 10 November 2011
Show/Hide Abstract | PDF Full-text (322 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Hsp90 Inhibitors)
p. 1400-1422
by  and
Pharmaceuticals 2011, 4(11), 1400-1422; doi:10.3390/ph4111400
Received: 31 August 2011; in revised form: 4 October 2011 / Accepted: 17 October 2011 / Published: 25 October 2011
Show/Hide Abstract | Cited by 8 | PDF Full-text (384 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Hsp90 Inhibitors)
p. 1281-1292
by ,  and
Pharmaceuticals 2011, 4(10), 1281-1292; doi:10.3390/ph4101281
Received: 8 August 2011; in revised form: 7 September 2011 / Accepted: 19 September 2011 / Published: 26 September 2011
Show/Hide Abstract | Cited by 1 | PDF Full-text (610 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Hsp90 Inhibitors)
abstract graphic
Select/unselect all
Displaying article 1-8
Select articles Export citation of selected articles as:

Last update: 4 March 2014

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert